Piramal Pharma Ltd vs Valiant Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 10, 2026

Key Highlights

The Latest Trading Price of Piramal Pharma Ltd is ₹ 179.75 as of 08 May 15:30 . The P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 yearsThe P/E Ratio of Valiant Laboratories Ltd changed from 2080 on March 2024 to 0 on March 2025 . This represents a CAGR of -100.00% over 2 years The Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 yearsThe Market Cap of Valiant Laboratories Ltd changed from ₹ 632.63 crore on March 2024 to ₹ 333.65 crore on March 2025 . This represents a CAGR of -27.38% over 2 years The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The revenue of Valiant Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 53.09 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The ebitda of Valiant Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -0.26 crore. This represent the decline of -100% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The net profit of Valiant Laboratories Ltd changed from ₹ -0.51 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 yearsThe Dividend Payout of Valiant Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

About Valiant Laboratories Ltd

Valiant Laboratories Limited was originally formed as a Partnership Firm as M/s.
Bharat Chemicals' through deed of partnership dated October 17, 1980.
The said Partnership Firm, M/s.
Bharat Chemicals thereafter converted into a Public Company to 'Valiant Laboratories Limited' via Certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies. The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol.
The Company gradually, commenced manufacturing of Paracetamol by late 1982.

FAQs for the comparison of Piramal Pharma Ltd and Valiant Laboratories Ltd

Which company has a larger market capitalization, Piramal Pharma Ltd or Valiant Laboratories Ltd?

Market cap of Piramal Pharma Ltd is 23,893 Cr while Market cap of Valiant Laboratories Ltd is 441 Cr

What are the key factors driving the stock performance of Piramal Pharma Ltd and Valiant Laboratories Ltd?

The stock performance of Piramal Pharma Ltd and Valiant Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Piramal Pharma Ltd and Valiant Laboratories Ltd?

As of May 10, 2026, the Piramal Pharma Ltd stock price is INR ₹179.75. On the other hand, Valiant Laboratories Ltd stock price is INR ₹81.25.

How do dividend payouts of Piramal Pharma Ltd and Valiant Laboratories Ltd compare?

To compare the dividend payouts of Piramal Pharma Ltd and Valiant Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.